title: Lenalidomide in treating patients with castration-resistant prostate cancer.
abstract: BACKGROUND
  This analysis was conducted to evaluate the efficacy and safety of lenalidomide based regimen in treating patients with castration-resistant prostate cancer.
  
  
  METHODS
  Clinical studies evaluating the efficacy and safety of lenalidomide based regimens on response and safety for patients with castration-resistant prostate cancer were identified using a predefined search strategy. A pooled response rate (rate of PSA level decline of ≥50%) to treatment was calculated.
  
  
  RESULTS
  In lenalidomide based regimen, 3 clinical studies which including 98 patients with castration-resistant prostate cancer were considered eligible for inclusion. These lenalidomide based regimens included cisplatin, doxorubicin, or GM-CSF. Pooled analysis suggested that, in all patients, the pooled PSA level decline of ≥50% was 13.3% (13/98) in lenalidomide based regimens. Fatigue, nausea and vomitting were the main side effects. No grade III or IV renal or liver toxicity were observed. No treatment related death occurred in patients with lenalidomide based regimens.
  
  
  CONCLUSIONS
  This evidence based analysis suggests that lenalidomide based regimens are associated with mild response rate and acceptable toxicities for treating patients with castration-resistant prostate cancer.
authors.affiliation: Department of Urology, the Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, China E-mail : dongkui_765@163.com.
authors.forename: Dong-Liang
authors.initials: DL
authors.lastname: Xing
authors.forename: Dong-Kui
authors.initials: DK
authors.lastname: Song
authors.forename: Li-Rong
authors.initials: LR
authors.lastname: Zhang
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005500:Follow-Up Studies; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D015201:Meta-Analysis as Topic; D009367:Neoplasm Staging; D011379:Prognosis; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000473:pathology; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D013792:Thalidomide; D004317:Doxorubicin; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D000077269:Lenalidomide; D002945:Cisplatin